[1]
|
A. W. MacKenzie and R. B. Stoughton, “A Method for Comparing Percutaneous Absorption of Steroids,” Archives of Dermatology, Vol. 86, No. 11, 1962, pp. 608-610.
doi:10.1001/archderm.1962. 01590110044005
|
[2]
|
A. W. McKenzie, “Percutaneous Absorption of Steroids,” Archives of Dermatology, Vol. 86, No. 11, 1962, pp. 611-614. doi:10.1001/archderm.1962.01590110047006
|
[3]
|
S. Wiedersberg, C. S. Leopold and R. H. Guy, “Bioavailability and Bioequivalence of Topical Glucocorticoids,” European Journal of Pharmaceutics and Biopharmaceutics, Vol. 68, No. 3, 2008, pp. 453-466.
doi:10.1016/j.ejpb.2007.08.007
|
[4]
|
Y. Narkar, “Bioequivalence for Topical Products—An Update,” Pharmaceutical Research, Vol. 27, No. 12, 2010, pp. 2590-2601. doi:10.1007/s11095-010-0250-3
|
[5]
|
Organisation for Economic Co-operation and Development (OECD), “Test Guideline 427: In Vitro Method,” Paris, 2004.
|
[6]
|
T. J. Franz, P. A. Lehman and S. G. Raney, “Use of Excised Human Skin to Assess the Bioequivalence of Topical Products,” Skin Pharmacology and Physiology, Vol. 22, No. 5, 2009, pp. 276-286. doi:10.1159/ 000235828
|
[7]
|
A. Le Quellec, S. Dupin, P. Genissel, S. Saivin, B. Marchand and J. P. M. Houin, “Microdialysis Probes Calibration: Gradient and Tissue Dependent Changes in No Flux and Reverse Dialysis Methods,” Journal of Pharmacoogical and Toxicological Methods, Vol. 33, No. 1, 1995, pp. 11-16. doi:10.1016/1056-8719(94)00049-A
|
[8]
|
N. Leveque, S. Makki, J. Hadgraft and P. Humbert, “Comparison of Franz Cells and Microdialysis for Assessing Salicylic Penetration through Human Skin,” International Journal of Pharmaceutics, Vol. 269, No. 2, 2004, pp. 323-328. doi:10.1016/j.ijpharm.2003.09.012
|
[9]
|
I. Brody, “Mast Cell Degranulation in the Evolution of Acute Eruptive Guttate Psoriasis Vulgaris,” Journal of Investigative Dermatology, Vol. 82, No. 5, 1984, pp. 460464. doi:10.1111/1523-1747.ep12260955
|
[10]
|
A. L. Krogstad, G. Lonnroth, B. F. G. Larson and B. G. Wallin, “Nerve-Induced Histamine Release Is of Little Importance in Psoriatic Skin,” British Journal of Dermatology, Vol. 139, No. 5, 1998, pp. 403-409.
doi:10.1046/j.1365-2133.1998.02402.x
|
[11]
|
T. Ishizaka, D. H. Conrad, T. F. Huff, D. D. Metcalfe, R. L. Stevens and R. A. Lewis, “Unique Features of Human Basophilic Granulocytes Developed in in Vitro Culture,” International Archives of Allergy and Applied Immunology, Vol. 77, No. 1-2, 1985, pp. 137-143.
doi:10.1159/000233768
|
[12]
|
L. J. Petersen, K. Brasso, M. Pryds and P. S. Skov, “Histamine Release in Intact Human Skin by Monocyte Chemoattractant Factor-1, RANTES, Macrophage Inflammatory Protein-1 Alpha, Stem Cell Factor, Anti-IgE, and Codeine as Determined by an ex Vivo Skin Microdialysis Technique,” Journal of Allergy and Clinical Immunology, Vol. 98, No. 4, 1996, pp. 790-796.
doi:10.1016/S0091-6749(96)70128-8
|
[13]
|
L. K. Pershing, B. S. Silver, G. G. Krueger, V. P. Shah and J. P. Skelly, “Feasibility of Measuring the Bioavailability of Topical Betamethasone Dipropionate in Commercial Formulations Using Drug Content in Skin and a Blanching Bioassay,” Pharmaceutical Research, Vol. 9, No. 1, 1992, pp. 45-51. doi:10.1023/ A:1018975626210
|
[14]
|
B. W. Barry and R. Woodford, “Activity and Bioavailability of Topical Corticosteroids: In Vivo/In Vitro Correlations for the Vasoconstrictor Test,” Journal of Clinical Pharmacology, Vol. 3, No. 1, 1978, pp. 43-65.
|
[15]
|
K. H. Burdick, “Corticosteroid Bioavailability Assays: Correlation with a Clinical Study,” Acta Dermato-Venereologica: Supplement (Stockholm), Vol. 52, No. 67, 1971, pp. 19-23.
|
[16]
|
B. W. Barry, “Bioavailability of Topical Steroids,” Dermatologica, Vol. 152, Suppl. 1, 1976, pp. 47-65.
doi:10.1159/000257866
|
[17]
|
G. L. Coleman, I. Kanfer and J. M. Haigh, “Comparative Blanching Activities of Proprietary Diflucortolone Valerate Topical Preparations,” Dermatologica, Vol. 156, No. 4, 1978, pp. 224-230. doi:10.1159/ 000250920
|
[18]
|
E. Meyer, A. D. Magnus, J. M. Haigh and I. Kanfer, “Comparison of the Blanching Activities of Dermovate, Betnovate and Eumovate Creams and Ointments,” International Journal of Pharmaceutics, Vol. 41, No. 1, 1988, pp. 63-66. doi:10.1016/0378-5173(88)90136-6
|
[19]
|
E. W. Smith, E. Meyer, J. M. Haigh and H. I. Maibach, “The Human Skin Blanching Assay as an Indicator of Topical Corticosteroid Bioavailability and Potency: An Update,” In: R. L. Bronaugh and H. I. Maibach, Eds., Percutaneous Absorption: Mechanisms, Methodology and Drug Delivery, 2nd Edition, Marcel Dekker, Inc., New York, 1989, pp. 443-460.
|
[20]
|
J. M. Haigh and L. Kanfer, “Assessment of Topical Corticosteroid Preparations: The Human Skin Blanching Assay,” International Journal of Pharmaceutics, Vol. 19, No. 3, 1984, pp. 245-262.
doi:10.1016/ 0378-5173(84)90055-3
|